• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Crowd-sourced diabetes app Nightscout details talks with FDA, development

Crowd-sourced diabetes app Nightscout details talks with FDA, development

April 14, 2016 By Fink Densford

NightScoutOpen-source diabetes app developer Nightscout detailed their development process, including crowdsourcing and their talks with the FDA in a new editorial from the Journal of the American Medical Association.

In the article, NightScout foundation prez James Wedding and Dr. Joyce Lee and Emily Hirschfield from the University of Michigan discuss the patient-led initiative during its 2-years in development.

NightScout is an open-source software program that hacks into a Dexcom Inc. (NSDQ:DXCM) monitor and uploads its data to the internet. The information can then be relayed to smart phones and devices, allowing diabetic patients to monitor their blood sugar levels wherever they are.

In the JAMA article, the authors detail the growth from a 40-member Facebook group to a whopping 15,000 members after 18 months, seeing continued growth despite larger CGM companies coming forward to offer official, FDA-approved alternatives, as well as their interactions with the FDA.

“The FDA emphasized the need for a single entity, even if the entity is nontraditional, to be responsible for ensuring the safety and effectiveness of the project, which includes the reviewing and testing of code before public release, monitoring safety, detailing how quickly problems are identified and addressed in the system, tracking the code updates, and identifying the responsible party for these updates. The group has embarked on this process, but to date, there is no systematic measurement or monitoring of these events inside the community except for the unstructured information being shared by the Facebook group,” Authors write in the editorial.

Despite being open-sourced and crowd-developed, liability and safety concerns loom – but no one group or person can be held responsible for the collaborative project. Questions around this topic were discussed between leaders of the project and the FDA, the editorial authors wrote.

“The Nightscout community leadership has engaged with the FDA on a regular basis with the hope of receiving approval for Nightscout for monitoring purposes, which would reflect an important milestone for patient-driven design. In addition, a collaborative approach to patient-driven research is being explored jointly by the community with researchers. As the Nightscout Project continues to develop and unfold, the questions it raises should lead to greater opportunities for patients and their families to help drive innovation in the health care delivery system,” authors concluded.

Filed Under: Diabetes Tagged With: Journal of the American Medical Assn. (JAMA), Nightscout Project

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy